Depomed Fingers Lupin In Diabetes Drug Patent Case

Law360, New York (November 30, 2009, 5:32 PM EST) -- Depomed Inc. has accused generic-drug maker Lupin Ltd. of infringing four patents for control-release drug delivery technology used in the specialty pharmaceutical company's type 2 diabetes drug Glumetza.

The Menlo Park, Calif.-based drugmaker sued Lupin on Wednesday in the U.S. District Court for the Northern District of California, asking the court to enjoin the generic drugmaker from selling the allegedly infringing drugs.

Lupin's abbreviated new drug application to the U.S. Food and Drug Administration to market generic metformin hydrochloride tablets prompted Depomed's suit. The generic drug...
To view the full article, register now.